Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COLOVAGE vs ALPHACAINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
COLOVAGE is a bowel cleansing preparation containing polyethylene glycol 3350 and electrolytes. It acts as an osmotic laxative, causing fluid retention in the colon to stimulate bowel evacuation.
Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.
Colonoscopy preparation,Bowel cleansing prior to colorectal surgery
Local anesthesia by infiltration or nerve block,Spinal anesthesia,Epidural anesthesia
4 liters of PEG-3350 electrolyte solution orally as a single dose for colon cleansing prior to colonoscopy; alternatively, 2 liters with ascorbic acid regimen.
1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).
Not applicable (non-absorbed, gut lavage); systemic absorption minimal
Terminal half-life 2.5-3.5 hours in adults; prolonged to 4-6 hours in hepatic impairment or elderly.
Polyethylene glycol 3350 is not absorbed systemically; no hepatic metabolism.
Hydrolyzed by plasma pseudocholinesterases to para-aminobenzoic acid and diethylaminoethanol.
Primarily fecal as unabsorbed drug; negligible renal excretion (<5%)
Primarily renal excretion of unchanged drug and metabolites (70-80%); minor biliary elimination (10-15%); fecal excretion <5%.
Not applicable (minimal systemic absorption)
90-95% bound to alpha-1-acid glycoprotein and albumin.
Not applicable (limited to gastrointestinal tract)
Vd 0.8-1.2 L/kg; extensive tissue distribution (liver, lungs, brain).
Oral: <0.3% systemically absorbed
Oral: 30-40% (first-pass metabolism); Intramuscular: 85-95%; Intravenous: 100%.
Contraindicated in GFR <30 m L/min/1.73 m²; for GFR 30-60 m L/min/1.73 m², use with caution due to risk of electrolyte imbalance, no dose adjustment recommended.
No specific dose adjustment required; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation. Monitor for CNS toxicity.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to potential fluid and electrolyte disturbances.
Child-Pugh Class A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or use alternative agent.
Not indicated for patients under 18 years of age; no established weight-based dosing.
Local infiltration: 0.5–2% solution, maximum 4.5 mg/kg (without epinephrine) or 7 mg/kg (with epinephrine). For nerve blocks: weight-based dosing, not to exceed adult maximum.
No specific dose adjustment, but monitor for electrolyte disturbances, dehydration, and aspiration risk; consider split-dose regimen or lower volume if tolerated.
Reduce total dose by 20–30% due to decreased clearance and increased sensitivity; monitor for prolonged effect and toxicity.
Risk of fluid and electrolyte abnormalities (e.g., hyponatremia, seizures) in patients with impaired renal function, dehydration, or those taking medications affecting electrolytes.
Not available.
Monitor for fluid and electrolyte disturbances, especially in elderly, debilitated, or renal impaired patients. Use with caution in patients with gastrointestinal obstruction, ileus, or severe colitis.
Risk of systemic toxicity if absorbed into circulation,Hypersensitivity to ester-type anesthetics,Potential for methemoglobinemia with high doses,Use with caution in patients with impaired cardiac or hepatic function
Gastrointestinal obstruction, ileus, gastric retention, bowel perforation, toxic colitis or megacolon, hypersensitivity to any component.
Hypersensitivity to ester-type anesthetics or para-aminobenzoic acid,Severe hypotension,Bleeding disorders (for spinal/epidural use),Infection at the injection site
Only clear liquids (e.g., water, clear broth, black coffee/tea, clear juices) are allowed during bowel preparation. Avoid all solid foods, dairy products, red or purple liquids, and alcohol. Do not consume any food containing pulp or seeds.
No known food interactions. Avoid excessive grapefruit or grapefruit juice consumption due to potential CYP3A4 inhibition.
Colovage (polyethylene glycol 3350) is not absorbed systemically; no teratogenic risk anticipated in any trimester. No fetal risks reported with oral use.
Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in first trimester if possible.
Due to lack of systemic absorption, excretion into breast milk is negligible. Colovage is considered compatible with breastfeeding. M/P ratio: not applicable.
Excreted in breast milk in low amounts; M/P ratio not established. Consider risk-benefit; monitor infant for central nervous system depression.
No dose adjustment necessary; pharmacokinetics unchanged as drug is not absorbed.
No specific dose adjustments required; pharmacokinetics may be altered but clinical significance unclear.
COLOVAGE (polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, ascorbic acid) is a high-volume colon cleansing preparation. Ensure adequate hydration before, during, and after use. Monitor for electrolyte disturbances in patients with renal impairment or those taking diuretics. Split-dose regimen improves tolerance and cleansing quality. Avoid use in patients with gastrointestinal obstruction, perforation, or toxic megacolon.
Alphacaine Hydrochloride is an amide-type local anesthetic similar to lidocaine. Onset of action is 2-5 minutes with duration of 30-120 minutes depending on concentration and use of epinephrine. It is hepatically metabolized (CYP3A4) and renally excreted. Dose adjustment required in hepatic impairment. Risk of methemoglobinemia, especially in infants and patients on sulfonamides. Do not exceed maximum doses: 4.5 mg/kg plain, 7 mg/kg with epinephrine.
Follow the split-dose regimen exactly as prescribed to achieve optimal bowel cleansing.,Drink additional clear liquids as directed to prevent dehydration.,Do not eat any solid food while taking the preparation; only clear liquids are allowed.,Expect frequent, watery stools; stay near a restroom.,Contact your doctor if you experience severe abdominal pain, vomiting, or signs of dehydration.
Avoid alcohol consumption for 24 hours after procedure.,Inform your doctor if you have liver disease, heart block, or history of methemoglobinemia.,Do not drive or operate machinery until effects wear off.,Report numbness, tingling, or twitching immediately.,For dental procedures: avoid eating until numbness resolves to prevent injury.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COLOVAGE vs ALPHACAINE HYDROCHLORIDE, answered by our medical review team.
COLOVAGE is a Osmotic Laxative that works by COLOVAGE is a bowel cleansing preparation containing polyethylene glycol 3350 and electrolytes. It acts as an osmotic laxative, causing fluid retention in the colon to stimulate bowel evacuation.. ALPHACAINE HYDROCHLORIDE is a Local Anesthetic that works by Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COLOVAGE and ALPHACAINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COLOVAGE is: 4 liters of PEG-3350 electrolyte solution orally as a single dose for colon cleansing prior to colonoscopy; alternatively, 2 liters with ascorbic acid regimen.. The standard adult dose of ALPHACAINE HYDROCHLORIDE is: 1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COLOVAGE and ALPHACAINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COLOVAGE is classified as Category C. Colovage (polyethylene glycol 3350) is not absorbed systemically; no teratogenic risk anticipated in any trimester. No fetal risks reported with oral use.. ALPHACAINE HYDROCHLORIDE is classified as Category C. Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.